Vivo Capital

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.